PT - JOURNAL ARTICLE AU - Chang, Taehee AU - Cho, Sung-il AU - Min, Kyung-Duk TI - Implications of predator species richness in terms of zoonotic spillover transmission of filoviral hemorrhagic fevers in Africa AID - 10.1101/2023.02.12.23285832 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.12.23285832 4099 - http://medrxiv.org/content/early/2023/02/16/2023.02.12.23285832.short 4100 - http://medrxiv.org/content/early/2023/02/16/2023.02.12.23285832.full AB - Previous studies found that higher species richness of predators could reduce spillover risks of rodent-borne diseases. However, the effects on bat-borne diseases remains to be investigated. To this regard, we evaluated associations between predator species richness and the spillover events of Ebolavirus and Marburgvirus, the highly pathogenic bat-borne diseases in Africa. Stacked species distribution model approach was used to estimate predator species richness and Logistic regression analyses that considered spatiotemporal autocorrelations were conducted. The results showed that the third quartile (OR = 0.02, 95% CI 0.00–0.84) and fourth quartile (0.07, 0.00–0.42) of species richness of Strigiformes and the third quartile (0.15, CI 0.01–0.73) and fourth quartile (0.53, 0.03–0.85) of Colubridae showed significantly lower risks of spillover transmission of Ebolavirus. However, no significant association was found between predator species richness and Marburgvirus spillover. The results support a possible effect of predator species diversity on spillover suppression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (no. NRF-2021R1C1C2012611).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors